1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/9
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.
High
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.
1/9
07:18 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.
High
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.
1/9
05:58 am
mltx
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
High
Report
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
1/9
05:55 am
mltx
Rating for MLTX
High
Report
Rating for MLTX
1/8
09:07 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
11/6
10:12 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..